Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (February 28th Preview)
-
Generate’s $400M IPO: AI drug designer backs late‑stage asthma push
Generate Biomedicines priced a $400 million IPO to fund pivotal trials of its TSLP‑targeting antibody GB‑0895 and expand its AI‑driven protein design platform. The Flagship Pioneering‑backed company said it will allocate the bulk of proceeds to two phase‑3 asthma studies and to advancing a Phase 1b COPD program. Generate framed the offering as strategic capital to complete registrational work and further platform innovation.
-
EMA recommends Moderna’s mCombriax — first flu/COVID combo on the table
The European Medicines Agency’s CHMP recommended Moderna’s mCombriax, a combined mRNA influenza and COVID‑19 vaccine for adults 50 and older. Moderna said the opinion reflects trial data showing antibody responses against both viruses; the decision now moves to the European Commission for final approval. The recommendation follows a difficult regulatory path in the U.S., where Moderna has faced additional data requests from the FDA.
-
Atrium rises from Avidity deal: RNA heart programs keep going
Atrium Therapeutics launched after Novartis closed its acquisition of Avidity Biosciences, taking on Avidity’s cardiac RNA delivery programs and a public listing. The new company started operations with roughly $270 million in cash and two preclinical programs targeting PRKAG2 syndrome and PLN cardiomyopathy, diseases with no approved disease‑modifying therapies. Atrium’s leadership includes former Avidity executives and aims to leverage Avidity’s muscle‑targeted RNA delivery know‑how for cardiac indications.
-
Earendil and WuXi XDC ink up to $885M ADC pact
AI‑driven biologics developer Earendil Labs secured an exclusive license to WuXi XDC’s WuXiTecan‑2 payload‑linker technology and CRDMO services in a deal worth up to $885 million in upfront and milestone payments plus tiered royalties. The agreement gives Earendil access to a linker‑payload platform intended to accelerate next‑generation antibody‑drug conjugates and will see WuXi XDC support manufacturing. Both companies cited the pact as a route to speed ADC development for multiple oncology targets.
-
Systimmune’s iza‑bren clears phase III goals in China — survival endpoints met
Systimmune reported that izalontamab brengitecan (iza‑bren), its next‑generation antibody‑drug conjugate, met both progression‑free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple‑negative breast cancer. The readout supports the drug’s licensing relationship with Bristol Myers Squibb and positions iza‑bren as a potential new option in a hard‑to‑treat population. The company highlighted the positive survival data as a regulatory and commercial inflection point for the program.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.